Results 11 to 20 of about 1,060,485 (284)

An inhibitor of complement C5 provides structural insights into activation [PDF]

Proceedings of the National Academy of Sciences, 2019
The complement system is a crucial part of innate immune defenses against invading pathogens. The blood-meal of the tick Rhipicephalus pulchellus lasts for days, and the tick must therefore rely on inhibitors to counter complement activation. We have identified a class of inhibitors from tick
Reichhardt, M, Johnson, S, Tang, T, Morgan, T, Tebeka, N, Popitsch, N, Deme, J, Jore, M, Lea, S   +8 more
core   +10 more sources

Complement Inhibitor of C5 Activation from the Soft Tick Ornithodoros moubata [PDF]

The Journal of Immunology, 2005
Abstract Blood-feeding ticks must control C activation or be damaged by the host inflammatory response. We report the characterization and expression of a novel, relatively small, broad-acting C inhibitory protein (termed OmCI) from the soft tick Ornithodoros moubata.
Nunn, M, Sharma, A, Paesen, G, Adamson, S, Lissina, O, Willis, A, Nuttall, P   +6 more
openaire   +5 more sources

Therapeutic Development of Complement C5 Inhibitor CoversinTM with Extended Half-Life Via PASylation®

Blood, 2016
Abstract The complement C5 inhibitor Coversin is in clinical development for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and has been shown to be safe and effective in phase 1 single dose and multiple dose trials in healthy volunteers. A single phase 2 PNH patient, resistant to the standard of care eculizumab, has been treated
Nunn Miles, Arne Skerra
core   +5 more sources

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. [PDF]

Kidney Int Rep, 2021
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in ...
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D, 311 Study Group Members.   +11 more
europepmc   +2 more sources

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network

Frontiers in Immunology
ObjectiveTo integrate pharmacovigilance and network pharmacology methods for a comprehensive analysis of the potential adverse reactions of complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors ...
Luqiong Wang, Jiaojiao Chen, Huixiang Li, Lin Wang, Feiyu Liu, Xiaoli Jiang   +5 more
doaj   +4 more sources

Complement Component 5 (C5) Deficiency Improves Cognitive Outcome After Traumatic Brain Injury and Enhances Treatment Effects of Complement Inhibitors C1-Inh and CR2-Crry in a Mouse Model

Neurotrauma Reports, 2023
A potent effector of innate immunity, the complement system contributes significantly to the pathophysiology of traumatic brain injury (TBI). This study investigated the role of the complement cascade in neurobehavioral outcomes and neuropathology after ...
Min Chen, Stephen R. Edwards, Dhiraj Maskey, Trent M. Woodruff, Stephen Tomlinson, David Reutens   +5 more
doaj   +1 more source

Application of C5 inhibitors in glomerular diseases in 2021 [PDF]

Kidney Research and Clinical Practice, 2022
The complement pathway is an essential mechanism in innate immunity, but it is also involved in multiple pathologies. For kidney diseases, strong evidence of a dysregulation in the alternative pathway in atypical hemolytic uremic syndrome (aHUS) led to ...
Alexis Werion, Eric Rondeau
doaj   +1 more source

Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices

Frontiers in Immunology, 2021
Complement activation is key to anti-microbial defenses by directly acting on microbes and indirectly by triggering cellular immune responses. Complement activation may also contribute to the pathogenesis of numerous inflammatory and immunological ...
Sinan Muldur, Sinan Muldur, Douangsone D. Vadysirisack, Sharan Ragunathan, Yalan Tang, Alonso Ricardo, Camil Elie Sayegh, Daniel Irimia, Daniel Irimia   +8 more
doaj   +1 more source

Terminal Complement Activation Is Induced by Factors Released from Endplate Tissue of Disc Degeneration Patients and Stimulates Expression of Catabolic Enzymes in Annulus Fibrosus Cells

Cells, 2023
Terminal complement complex (TCC) deposition was identified in human degenerated discs. To clarify the role of terminal complement activation in disc degeneration (DD), we investigated respective activating mechanisms and cellular effects in annulus ...
Amelie Kuhn, Jana Riegger, Graciosa Q. Teixeira, Markus Huber-Lang, John D. Lambris, Cornelia Neidlinger-Wilke, Rolf E. Brenner   +6 more
doaj   +1 more source

Inhibitors of C5 complement enhance vaccinia virus oncolysis [PDF]

Cancer Gene Therapy, 2013
Genetically engineered tumor-selective vaccinia virus (VV) has been demonstrated to be a highly effective oncolytic agent, but immune clearance may limit its therapeutic potential. As previously demonstrated, immunosuppression can lead to significant enhancement of viral recovery and therapeutic effect, but the magnitude of complement-mediated viral ...
D, Magge, Z S, Guo, M E, O'Malley, L, Francis, R, Ravindranathan, D L, Bartlett   +5 more
openaire   +2 more sources